Literature DB >> 8798582

Sensitivity of opioid receptor-like receptor ORL1 for chemical modification on nociceptin, a naturally occurring nociceptive peptide.

Y Shimohigashi1, R Hatano, T Fujita, R Nakashima, T Nose, T Sujaku, A Saigo, K Shinjo, A Nagahisa.   

Abstract

Nociceptin or orphanin FQ is a novel neuropeptide that activates an opioid-like G protein-coupled receptor ORL1. This heptadecapeptide FGGFTGARKSARKLANQ resembles kappa-opioid peptide dynorphin A but exhibits an opposite effect to make animals hyperreactive to nociceptive stimulations (Meunier, J.-C., Mollereau, C., Toll, L., Suaudeau, C., Moisand, C., Alvinerie, P., Butour, J.-L., Guillemot, J.-C., Ferrara, P., Monsarrat, B., Mazarguil, H., Vassart, G., Parmentier, M., and Costentin, J. (1995) Nature 377, 532-535; Reinscheid, R. K., Nothacker, H.-P., Bourson, A., Ardati, A., Henningsen, R. A., Bunzow, J. R., Grandy, D. K., Langen, H., Monsma, F. J., Jr., and Civelli, O. (1995) Science 270, 792-794). In the present study, it was found that guinea pig brain contains receptors to which nociceptin binds much more strongly than to ORL1 receptors expressed in human 293 cells. Although the Tyr1 --> Phe substitution for dynorphin A eliminates almost completely an ability to bind to opioid receptors, the Phe1 --> Tyr substitution in nociceptin was found to retain almost fully both receptor binding affinity and in vivo hyperalgesic activity in tail-flick assay. Nociceptin was extremely weak to bind to opioid receptors, while Tyr1-nociceptin exhibited 10-40 times increased affinity, especially for mu receptors, due to its N-terminal sequential identity to opioid peptides. Shortened analogs of dynorphin A are known to retain receptor binding ability and analgesic activity, whereas the removal of C-terminal hexa- or decapeptide from nociceptin totally abolished the affinity for the ORL1 receptor. These results indicated that the mode of interaction between nociceptin and ORL1 receptor is quite different from that between dynorphin and opioid receptor and that the C-terminal portion of nociceptin is crucial for receptor recognition.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8798582     DOI: 10.1074/jbc.271.39.23642

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

Review 1.  Visualizing activation of opioid circuits by internalization of G protein-coupled receptors.

Authors:  Kevin Sinchak; Paul Micevych
Journal:  Mol Neurobiol       Date:  2003-04       Impact factor: 5.590

2.  Release of orphanin FQ/nociceptin in the medial preoptic nucleus and ventromedial nucleus of the hypothalamus facilitates lordosis.

Authors:  Kevin Sinchak; Phoebe Dewing; Misty Cook; Paul Micevych
Journal:  Horm Behav       Date:  2006-12-22       Impact factor: 3.587

Review 3.  Pharmacology of nociceptin and its receptor: a novel therapeutic target.

Authors:  G Calo'; R Guerrini; A Rizzi; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

4.  Further characterization of the ORL1 receptor-mediated inhibition of noradrenaline release in the mouse brain in vitro.

Authors:  S Werthwein; U Bauer; M Nakazi; M Kathmann; E Schlicker
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

5.  Transcriptional regulation of the MET receptor tyrosine kinase gene by MeCP2 and sex-specific expression in autism and Rett syndrome.

Authors:  J T Plummer; O V Evgrafov; M Y Bergman; M Friez; C A Haiman; P Levitt; K A Aldinger
Journal:  Transl Psychiatry       Date:  2013-10-22       Impact factor: 6.222

6.  Neurotransmitters and Their Receptors - 2003.

Authors:  Zdravko Lackovic
Journal:  EJIFCC       Date:  2004-08-31

Review 7.  2',6'-dimethylphenylalanine: a useful aromatic amino Acid surrogate for tyr or phe residue in opioid peptides.

Authors:  Yusuke Sasaki; Akihiro Ambo
Journal:  Int J Med Chem       Date:  2012-04-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.